See the Complete Picture.
Published loading...Updated

First Personalized Gene Therapy Using Base Editing Shows Promising Results in Baby with Rare Disorder

  • A baby named KJ Muldoon from Clifton Heights, Pennsylvania, received a personalized gene editing therapy for severe CPS1 deficiency and is now growing well.
  • Doctors developed this treatment quickly using CRISPR to fix a critical genetic error that kills half of affected infants, addressing a condition affecting about one in a million babies.
  • The lipid nanoparticle-delivered therapy involved additional doses, enabling KJ to resume a more typical diet and demonstrate strong recovery from illnesses despite the challenges posed by CPS1.
  • Researchers noted the $800,000-plus cost was comparable to a liver transplant and expect expenses to decrease as production improves, with hopes to help the millions left behind by current treatments.
  • Experts said this case, published in the New England Journal of Medicine, represents a first step toward wider gene editing therapies for rare disorders despite existing barriers.
Insights by Ground AI
Does this summary seem wrong?

236 Articles

All
Left
45
Center
96
Right
22
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 59% of the sources are Center
59% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Nature broke the news in United Kingdom on Thursday, May 15, 2025.
Sources are mostly out of (0)